Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind ... 
MarketWatch (press release)
"The compelling results from this rigorously designed trial clearly demonstrate that the combination of bavituximab and docetaxel is more active than docetaxel alone in treating second-line non-small cell lung cancer. We saw twice as many patients ...
Peregrine Reports Positive Top-Line Data From Bavituximab Phase II Trial RTT News

all 7 news articles » 

Customized chemotherapy based on epidermal growth factor receptor mutation ... 
7thSpace Interactive (press release)
Activating epidermal growth factor receptor (EGFR) mutations in non-small-cell lung cancer (NSCLC) are associated with enhanced response to EGFR tyrosine-kinase inhibitors. We studied patients with advanced NSCLC for whom treatment was customized based ...

 

ArQule and Daiichi Sankyo Announce Completion of Patient Recruitment in Phase ... 
EON: Enhanced Online News (press release)
... Phase 3 MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC).

and more » 

Testing for mutations identified in squamous cell lung cancer tumors helps ... 
Medical Xpress
While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas ? the most common type of non-small cell lung cancer ? and have developed drugs that can successfully address them, scientists have not yet identified ...
Drug Combo Tackling Solid Tumors Drug Discovery & Development
New drugs combination trialed against lung cancer Private Healthcare UK
Combination of New Drug to Counter Lung Cancer TopNews Arab Emirates
IBTimes.co.uk  -Spire Healthcare 
all 23 news articles » 

Testing for Mutations Identified in Squamous Cell Lung Cancer Tumors Helps ... 
Newswise (press release)
While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas ? the most common type of non-small cell lung cancer ? and have developed drugs that can successfully address them, scientists have not yet identified ...
Lung Cancer, More Than Meets the Eye dailyRx

all 26 news articles » 

ArQule, Daiichi Sankyo complete patient recruitment in phase III MARQUEE trial ... 
pharmabiz.com
... phase III MARQUEE pivotal trial of their investigational selective c-MET inhibitor, tivantinib, in combination with erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC).
ArQule, Daiichi complete patient recruitment in Phase III NSCLC trial Pharmaceutical Business Review
ArQule ready for Phase 3 lung cancer trial Mass High Tech

all 4 news articles » 

Leading Researchers Address Hope For Early Detection and Treatments For Lung ... 
MarketWatch (press release)
Therapeutics: "The rate of progress in treating lung cancer is only accelerating," said Dr. Heymach, who received a 2011 LUNGevity research grant to help determine which non-small cell lung cancer patients are most likely to benefit from a VEGF ...

and more » 

Donna Summer: Lung cancer leading cause of cancer death 
Los Angeles Times
In 2012, the group estimates, there will be about 226000 new cases of lung cancer in the US Survival rates of people with lung cancer are low. Only about half of people diagnosed with early-stage non-small-cell lung cancer (the more common type) ...
Lung Cancer - Donna Summer's Last Dance dailyRx

all 4,021 news articles » 

Local girl travels to nation's capitol on lung cancer crusade 
Marietta Daily Journal
Kaylee knows firsthand the impact of lung cancer on a family. Two years ago today, her father Robb Morris, an All-American swimmer who never smoked, was diagnosed with Stage 4 non-small cell lung cancer. His story was profiled in Lifestyle on Oct. 21, ...

and more » 

RPT-Pfizer drug effective in rare children's cancers 
Reuters
Crizotinib, sold under the brand name Xalkori, is approved to treat non-small cell lung cancer in patients with a specific gene mutation known as ALK. But some patients with other types of cancer have also been found to have abnormal ALK, ...
Pfizer's targeted drug knocks out child cancers in small study FiercePharma
Complete responses in Phase I trial of crizotinib in rare childhood cancer The Pharma Letter

all 16 news articles »